secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K/A
Filed at:   2022-08-17T23:59:59+00:00
Accession:  0001438533-22-000036
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Therapeutics appoints Christopher Cline as CFO with $430k salary, equity grants
--------------------------------------------------------------------------------

- Christopher Cline named CFO effective September 1, 2022, replacing retiring Laura Clague.
- Annual base salary of $430,000; target annual bonus of 50% of base salary.
- Equity grants: stock option for 48,000 shares, Time-Based RSU for 5,000 shares, PSUs for 9,840 shares.
- Laura Clague steps down as CFO on August 31, 2022, remains through Q1 2023 for transition.
- Severance provisions include 12-month cash continuation and accelerated vesting under certain conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853322000036/0001438533-22-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853322000036/tvtx-20220419.htm
  HTML page:      https://secwatch.observer/filing/0001438533-22-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer